CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target
-
- Melissa Chua
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Charina Ortega
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Ayesha Sheikh
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Migi Lee
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Hussein Abdul-Rassoul
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Kevan Hartshorn
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
-
- Isabel Dominguez
- Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
説明
<jats:p>CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors.</jats:p>
収録刊行物
-
- Pharmaceuticals
-
Pharmaceuticals 10 (1), 18-, 2017-01-28
MDPI AG
